Related Experiment Video
Updated: Feb 11, 2026

Isolation of Murine Peritoneal Macrophages to Carry Out Gene Expression Analysis Upon Toll-like Receptors Stimulation
Published on: April 29, 2015
Targeting Toll-like Receptors in Cancer Prevention
Karen S Sfanos1,2,3
1Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland. ksfanos@jhmi.edu.
Abstract:
There is a pressing need for the development of new prevention strategies for the most common worldwide malignancy, nonmelanoma skin cancer (NMSC), as sun protection efforts have not proven to be completely effective. Interestingly, despite the known circumstance that individuals undergoing chronic immunosuppression are at a substantially increased risk for developing NMSC, in this issue of Cancer Prevention Research, Blohm-Mangone and colleagues provide new evidence that topical application of the Toll-like receptor 4 (TLR4) antagonist resatorvid may be efficacious as a chemopreventive agent in NMSC specifically via blocking UV-induced inflammatory signaling. These new findings highlight a potentially delicate dichotomy between the role of innate immune receptors in the normal, protective immunosurveillance of damaged cells in the skin and the pathogenic UV-induced overstimulation of cutaneous inflammation that promotes photocarcinogenesis. Given the tremendous cancer burden incurred by NMSC, further exploration of the use of TLR4 antagonists in NMSC chemoprevention strategies is certainly warranted. Cancer Prev Res; 11(5); 251-4. ©2018 AACRSee related article by Blohm-Mangone et al., p. 265.
Insights
New research suggests Toll-like receptor 4 (TLR4) antagonists, like resatorvid, may prevent nonmelanoma skin cancer (NMSC) by blocking UV-induced inflammation. This offers a promising new strategy for NMSC chemoprevention.
Area of Science:
- Immunology
- Dermatology
- Oncology
Background:
- Nonmelanoma skin cancer (NMSC) is a prevalent malignancy with incomplete prevention via sun protection.
- Individuals with chronic immunosuppression face a significantly higher risk of developing NMSC.
- UV radiation is a known carcinogen, inducing inflammatory signaling pathways implicated in skin cancer development.
Discussion:
- Blohm-Mangone and colleagues investigated the potential of Toll-like receptor 4 (TLR4) antagonist resatorvid for NMSC chemoprevention.
- Resatorvid demonstrated efficacy by blocking UV-induced inflammatory signaling, suggesting a novel therapeutic mechanism.
- The study highlights the complex role of innate immune receptors in skin cancer, balancing immunosurveillance with pathogenic inflammation.
Key Insights:
- Topical resatorvid shows promise as a chemopreventive agent against UV-induced NMSC.
- TLR4 antagonism may counteract the pro-carcinogenic inflammatory effects of UV radiation on the skin.
- Understanding the dichotomy of TLR4's role in immune response is crucial for targeted NMSC prevention.
Outlook:
- Further research into TLR4 antagonists is warranted for developing effective NMSC chemoprevention strategies.
- Exploring the therapeutic window and long-term effects of TLR4 antagonists in skin cancer prevention is essential.
- This research opens avenues for novel immunomodulatory approaches to combat skin carcinogenesis.
Related Concept Videos
Cancer Prevention
Some...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Internal Receptors
Prevention of Further Absorption of Poison
Preventive Healthcare Services
Receptor-mediated Endocytosis

